market re-rate, page-73

I’m still here sir. I don’t plan on leaving now or anytime soon.

the investment strategy in any biotech should be LONG. I do share frustrations regarding timeframes and time lines particularly relating to MK but short term SP spikes are rarely sustained . I would prefer a SP re rate backed by milestones and company objectives being met.
have we turned the corner ? Not sure YET but we have been Tokyo drifting for a while now.
disclosing : I’m here for a multi bagger
imho